LCMC3 study reported on the pathological and imaging response to different levels of PD-L1 expression as secondary endpoints, finding that high levels of PD-L1 expression was associated with MPR from neoadjuvant immunotherapy in patients with early stage NSCLC (45). Here, CD274 is linked to non-small cell lung carcinoma.